WASHINGTON — Republicans on the House Energy and Commerce Committee are gearing up to overhaul a controversial Medicare drug discount program as soon as this quarter, a key Republican tells STAT. That’s a win for drug makers who have long pushed to narrow the scope of the so-called 340B drug discount program.
At the same time, however, the committee will also examine whether to restore a recent $1.6 billion cut to the program, which came under a Trump administration rule that took effect Jan. 1, according to committee Chairman Greg Walden of Oregon. Hospital groups have called the cut “devastating” and have lobbied Congress to reverse it.
About the Author Reprints
